1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F: Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 2017, 71(1).
2. Lenis AT, Lec PM, Chamie K, Mshs MD: Bladder Cancer: A Review. JAMA 2020, 324(19):1980-1991.
3. Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Roupret M, Shariat SF, Sylvester R et al: European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019, 76(5):639-657.
4. Bandari J, Maganty A, MacLeod LC, Davies BJ: Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin. Eur Urol Focus 2018, 4(4):481-484.
5. Tan WS, Kelly JD: Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol 2018, 15(11):667-685.
6. Ba M, Cui S, Wang B, Long H, Yan Z, Wang S, Wu Y, Gong Y: Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection. Oncol Rep 2017, 37(5):2761-2770.
7. Ba M, Cui S, Long H, Gong Y, Wu Y, Lin K, Tu Y, Zhang B, Wu W: Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study. BMC Urol 2019, 19(1):126.
8. Ruan Q, Ding D, Wang B, He C, Ren X, Feng Z, Pang Z, Wang J, Zhang X, Tang H et al: A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer. Cancer Biol Med 2021, 18(1):308-317.
9. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49(3):466-465; discussion 475-467.
10. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J et al: Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009, 182(5):2195-2203.
11. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ et al: Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015, 67(1):74-82.
12. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S et al: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016, 69(1):60-69.
13. Garg T, McMullen CK, Leo MC, O'Keeffe-Rosetti MC, Weinmann S, Nielsen ME: Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort. Cancer 2021, 127(4):520-527.
14. Ravvaz K, Walz ME, Weissert JA, Downs TM: Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population. The Journal of urology 2017, 198(4):824-831.
15. Leo MC, McMullen CK, O'Keeffe-Rosetti M, Weinmann S, Garg T, Nielsen ME: External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system. Urol Oncol 2020, 38(2):39.e21-39.e27.
16. Wang H, Ding W, Jiang G, Gou Y, Sun C, Chen Z, Xu K, Xia G: EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification. Medicine (Baltimore) 2018, 97(36):e12006.
17. Ding W, Chen Z, Gou Y, Sun C, Xu K, Tan J, Tong S, Xia G, Ding Q: Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer? Cancer Epidemiol 2014, 38(2):157-161.
18. Kohjimoto Y, Kusumoto H, Nishizawa S, Kikkawa K, Kodama Y, Ko M, Matsumura N, Hara I: External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin. Int J Urol 2014, 21(12):1201-1207.
19. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH: The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010, 105(3):300-308.
20. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA: Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol 2016, 69(2):300-310.
21. van Osch FH, Jochems SH, van Schooten F-J, Bryan RT, Zeegers MP: Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 2016, 45(3):857-870.
22. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC: Association between smoking and risk of bladder cancer among men and women. JAMA 2011, 306(7):737-745.
23. Ali-El-Dein B, Sooriakumaran P, Trinh QD, Barakat TS, Nabeeh A, Ibrahiem el HI: Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre. BJU Int 2013, 111(8):E331-341.
24. Cui J, Chen S, Bo Q, Wang S, Zhang N, Yu M, Wang W, Han J, Zhu Y, Shi B: Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ. Onco Targets Ther 2017, 10:5541-5550.
25. Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH: Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system. World J Urol 2019, 37(9):1867-1877.